Kodiak Sciences Inc
K27
Company Profile
Business description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Contact
1200 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
121
Stocks News & Analysis
stocks
ASX listed gold miner under pressure due to lower production
Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,819.40 | 9.30 | -0.11% |
| CAC 40 | 7,974.49 | 38.52 | 0.49% |
| DAX 40 | 23,730.92 | 166.91 | 0.71% |
| Dow JONES (US) | 47,054.82 | 108.41 | 0.23% |
| FTSE 100 | 10,403.60 | 85.91 | 0.83% |
| HKSE | 25,868.54 | 34.52 | 0.13% |
| NASDAQ | 22,478.92 | 104.74 | 0.47% |
| Nikkei 225 | 53,700.39 | 50.76 | -0.09% |
| NZX 50 Index | 13,182.23 | 17.65 | 0.13% |
| S&P 500 | 6,719.67 | 20.29 | 0.30% |
| S&P/ASX 200 | 8,614.30 | 4.40 | -0.05% |
| SSE Composite Index | 4,049.91 | 34.88 | -0.85% |